<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20020723105231Z</creation_date><modification_date>D:20060321214816+01'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-00-131_h_w_dec_6.pdf</pdf_file></head><body><section><header>i</header></section><section><header>en</header><p>commission of the european communitiesbrussels, 19/07/2002c(2002) 2857
 not for publication</p></section><section><header>commission decisionof 19/07/2002
 amending decision c(2000)1407 on the marketing authorization for
 the medicinal product for human use
 &quot;pegintron - peginterferon alfa-2b&quot;
  (text with eea relevance)</header><p>only the french and the dutch texts are authentic.ii</p></section><section><header>commission decisionof 19/07/2002
 amending decision c(2000)1407 on the marketing authorization for
 the medicinal product for human use
 &quot;pegintron - peginterferon alfa-2b&quot;
  (text with eea relevance)</header><p>the commission of the european communities,having regard to the treaty establishing the european community,
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down
 community procedures for the authorization and supervision of medicinal products for
 human and veterinary use and establishing a european agency for the evaluation of
 medicinal products
 1, as amended by commission regulation (ec) no 649/982,having regard to commission regulation (ec) no 542/95 of 10 march 1995 concerning
 the examination of variations to the terms of a marketing authorisation falling within the
 scope of council regulation (eec) no 2309/93
 3, as amended by commissionregulation (ec) no 1069/98
 4, and in particular article 5(2) thereof,having regard to the opinion of the european agency for the evaluation of medicinal
 products,
 whereas:
 (1)</p><p>the medicinal product &quot;pegintron - peginterferon alfa-2b&quot; entered in the
 community register of medicinal products under nos eu/1/00/131/031-050
 authorised by commission decision c(2000)1407 of 25 may 2000, as amended,
 complies with the requirements set out in regulation (eec) no 2309/93.
 (2)</p><p>schering plough europe submitted an application on 30 may 2002 pursuant to
 article 4(1) set out in regulation (ec) no 542/95.
 (3)</p><p>the european agency for the evaluation of medicinal products delivered a
 favourable opinion formulated on 7 june 2002 by the committee for proprietary
 medicinal products,
 (4)</p><p>decision c(2000)1407 should therefore be amended accordingly.</p><p> 
 1 oj no l 214, 24. 8. 1993, p. 1.2 oj l 88, 24.3.1998, p. 7.3 oj no l 55, 11.3.1995, p. 154 oj l 153, 27.5.1998, p. 11iii(5)</p><p>in accordance with article 5(2) of regulation (ec) no 542/95, this decision shall
 take effect retroactively on the 31st day following receipt by the european
 agency for the evaluation of medicinal products of the application relating to it.
 has adopted this decision:
 article 1decision c(2000)1407 is amended as follows:1. annex i is replaced by the annex to this decision.
 article 2this decision shall apply from 29 june 2002.article 3this decision is addressed to schering plough europe, rue de stalle, 73, 1180bruxelles, belgique – stallestraat, 73 – 1180 brussel, belgië.
 done at brussels, 19/07/2002
 for the commissionerkki liikanen
 member of the commission</p></section></body></xml>